Skip to content

US · MDT · MEDICAL - DEVICES

Medtronic plc (MDT) intrinsic value and stock valuation

$99.94as of 2026-11-21 · Mkt cap 110.07B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Medtronic plc DCF and intrinsic value

InvestorsCraft values MDT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MDT’s statements →

Medtronic plc Graham Number

Graham Number: $57.37d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Galway, GA H91 4K49 medtronic.com

How the business is doing

Fiscal 2012–2026, USD

Revenue
$36.4B+3.8% 5y CAGRd
20122026
Net income
$4.8B+5.9% 5y CAGRd
20122026
Free cash flow
$5.43B+2.1% 5y CAGRd
20122026
Total equity
$50.1B-0.6% 5y CAGRd
20122026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2026, USD
20262025202420232022
Revenue$36.4B$33.5B$32.4B$31.2B$31.7B
Operating income$6.47B$5.96B$5.14B$5.49B$5.75B
Net income$4.8B$4.66B$3.68B$3.76B$5.04B
EPSd$3.73M$3.61M$2.76M$2.82M$3.73M
Operating cash flow$7.33B$7.04B$6.79B$6.04B$7.35B
Capital expenditure-$-1.9B-$-1.86B-$-1.59B-$-1.46B-$-1.37B
Free cash flow$5.43B$5.19B$5.2B$4.58B$5.98B
Total assets$93B$91.7B$90B$90.9B$91B
Total debt$28B$28.5B$25B$24.4B$24.1B
Net debt$26B$26.3B$23.7B$22.8B$20.4B
Total equity$50.1B$48.3B$50.4B$51.7B$52.7B
Cash and short-term investments$9.22B$8.97B$8.01B$7.96B$10.6B
Income statement
20262025202420232022
Revenue$36.4B$33.5B$32.4B$31.2B$31.7B
Cost of revenue$12.7B$11.6B$11.2B$10.7B$10.1B
Gross profit$23.6B$21.9B$21.1B$20.5B$21.5B
Research and development expenses$2.87B$2.73B$2.74B$2.7B$2.75B
Selling, general and administrative expenses$11.8B$10.8B$10.7B$10.4B$10.3B
Other expenses$2.52B$2.37B$2.53B$1.91B$2.75B
Operating expenses$17.2B$16B$16B$15B$15.8B
Cost and expenses$29.9B$27.6B$27.2B$25.7B$25.9B
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$715M$729M$719M$636M$553M
Depreciation and amortization$2.96B$2.86B$2.65B$2.7B$2.71B
Ebitda$9.81B$9.22B$8.2B$8.7B$8.78B
Operating income$6.47B$5.96B$5.14B$5.49B$5.75B
Total other income/expenses, net-$-331M-$-327M-$-307M-$-121M-$-235M
Income before tax$6.14B$5.63B$4.84B$5.36B$5.52B
Income tax expense$1.3B$936M$1.13B$1.58B$456M
Net income$4.8B$4.66B$3.68B$3.76B$5.04B
Weighted average shares outstanding$1.28B$1.29B$1.33B$1.33B$1.34B
Weighted average diluted shares outstanding$1.29B$1.29B$1.33B$1.33B$1.35B
Balance sheet
20262025202420232022
Cash and short-term investments$9.22B$8.97B$8.01B$7.96B$10.6B
Net receivables$6.64B$6.52B$6.13B$6B$5.55B
Inventory$5.95B$5.48B$5.22B$5.29B$4.62B
Total current assets$24.8B$23.8B$21.9B$21.7B$23.1B
Property, plant and equipment, net$7.42B$6.84B$6.13B$5.57B$5.41B
Goodwill and intangible assets$52.7B$53.4B$54.2B$56.3B$56.1B
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$68.2B$67.9B$68B$69.3B$67.9B
Total assets$93B$91.7B$90B$90.9B$91B
Accounts payable$2.64B$2.45B$2.41B$2.66B$2.28B
Short-term debt$1.79B$2.87B$1.09B$20M$3.74B
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$11.7B$12.9B$10.8B$9.05B$12.4B
Long-term debt$26.2B$25.6B$23.9B$24.3B$20.4B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$31.3B$30.5B$28.8B$30.2B$25.9B
Capital lease obligations$60M$58M$61M$64M$62M
Total liabilities$43B$43.4B$39.6B$39.3B$38.3B
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings$32.6B$31.5B$30.4B$30.4B$30.3B
Accumulated other comprehensive income (loss)-$-4.1B-$-4.28B-$-3.32B-$-3.5B-$-2.27B
Total equity$50.1B$48.3B$50.4B$51.7B$52.7B
Total investments$7.27B$6.75B$6.72B$6.42B$6.86B
Total debt$28B$28.5B$25B$24.4B$24.1B
Net debt$26B$26.3B$23.7B$22.8B$20.4B
Cash flow statement
20262025202420232022
Net income$4.84B$4.69B$3.68B$3.78B$5.06B
Depreciation and amortization$2.96B$2.86B$2.65B$2.7B$2.71B
Stock-based compensation$457M$429M$393M$355M$359M
Change in working capital-$-1.42B-$-1.05B-$-484M-$-967M-$-889M
Accounts receivable-$-200M-$-433M-$-391M-$-576M-$-477M
Inventory-$-404M-$-292M-$-139M-$-939M-$-560M
Accounts payable$46M$209M$391M$696M$213M
Net cash provided by operating activities$7.33B$7.04B$6.79B$6.04B$7.35B
Investments in property, plant and equipment-$-1.9B-$-1.86B-$-1.59B-$-1.46B-$-1.37B
Acquisitions, net-$-406M-$-98M-$-211M-$-1.87B-$-91M
Net cash used for investing activities-$-2.93B-$-1.94B-$-2.37B-$-3.49B-$-1.66B
Common stock issued$516M$508M$284M$308M$429M
Common stock repurchased-$-1.04B-$-3.24B-$-2.14B-$-645M-$-2.54B
Dividends paid-$-3.64B-$-3.59B-$-3.67B-$-3.62B-$-3.38B
Net cash used for financing activities-$-4.75B-$-4.36B-$-4.45B-$-4.96B-$-5.34B
Net change in cash-$-269M$934M-$-259M-$-2.17B$121M
Cash at end of period$1.95B$2.22B$1.28B$1.54B$3.71B
Operating cash flow$7.33B$7.04B$6.79B$6.04B$7.35B
Capital expenditure-$-1.9B-$-1.86B-$-1.59B-$-1.46B-$-1.37B
Free cash flow$5.43B$5.19B$5.2B$4.58B$5.98B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Medtronic plc

        Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.

        CEO
        Geoffrey Straub Martha
        Employees
        95K
        Beta
        0.58

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Medtronic plc (MDT)?

        InvestorsCraft does not currently publish an intrinsic value for MDT. How the IC value is calculated.

        Is MDT undervalued?

        InvestorsCraft does not publish an undervaluation signal for MDT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.